Changes of some Liver Function Tests with Regular and Irregular Desferroxamine Therapy in β-Thalassemic Patients
Keywords:
Desferroxamine Therapy, β-Thalassemic Patients, MosulAbstract
Background and Objectives: (a) To determine the effect of regular desferroxamine (DFO) therapy on De-Ritis ratio. (b) To determine the changes in some liver function test parameters between patient on regular DFO and those with irregular DFO therapy.(c)To determine the relation between serum iron and serum ferritin in both groups. (d) To determine the effects of age, sex and body mass index (BMI) on measured parameters in both groups.
Methods: This study was conducted at Thalassemia Center /Ibn-Al-atheer Pediatric-Hospital in Mosul from October 2007 to April 2008. Forty patients with β- Thalassemia were selected as follow: twenty patients with regular DFO therapy and other twenty with irregular DFO therapy.
Results: De-Ritis ratio serum Ferritin, Ferritin: total serum protein ratio and total serum protein shows no significant changes between both groups. Serum ALT, AST, ALP activities and serum iron shows significant increase in those with irregular DFO therapy (P< 0.01).
Conclusions:Irregular DFO therapy shows significant effects on serum iron and some other liver function test parameters that indicate chronic hepatocytes damage without changes in De-Ritis ratio which is used as indicator for acute hepatocytes damage.
Metrics
References
Olivieri NF, Brittenham GM. Iron chelation therapy and the treatment of thalassemia. Blood (1997) 89: 739-761.
Olivieri NF, Buncic JR, Chew E et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferroxamine infusion. N.Engl.J.Med (1986) 314:869-873.
Hartkamp M, Babyn P., Olivieri NF. Spinal deformities in desferroxamine treatment homozygns β- thalassemia major patients. Pediatr Radiol (1993) 23:525-528.
De-Sancitis V., Pinamonti A., Di Palma et al. Growth and development in thalassemia major patients with bone lesion due to desferroxamine. Eur J Pediatr (1996) 155:368-372.
Chan Y., Li C., Pang L. et al. Desferroxamine-induced long bone changes in thalassemic patient-radiographic features, prevalence and relation with growth. Clin Rad (2000) 55:610-614.
Poli G. Pathogenesis of liver fibrosis; role of oxidative stress. Mol Aspects Med. (2000) 2:49-98.
Jensen P., Jensen F., Christensen T. et al. Relationship between hepatocellular injury and transfusional iron overload prior and during iron chelation with desferroxamine: a study in adult patients with acquired anemia. Blood (2003) 101; 1:91-96.
Chan Y., Li C., Law M. et al. Liver volume in thalassemia major: relationship with body weight, serum ferritin and liver function test. Pediatr Radiol (2005) 35:165-168.
Stookey L. Ferrozine. A new spectrophotometric reagent for iron. Anal Chem (1970) 42:779-781.
Bemard A., Lanwerys R. Turbidimetery-Latex immunoassay for serum ferritin.J Immunol Methods (1984) 71:141-147.
Wootton I., Freeman H..Microanalysis in medical biochemistry. 6th ed. Curchill Livingstone, Edinburgh, England (1982). 102-105.
Kind R., King E. Estimation of plasma phosphatase by determination of hydrolysed phenol with aminoantipyrine. J. Clin Path (1954) 7:322-326.
Buritis C., Ashwood E. Tietz textbook of clinical chemistry. 3rd ed. Saunders Company, USA. (1999). 617-619.
Prati D., Taioli E., Zanella A. et al. Updated definition of healthy ranges for serum alavin-aminotransfarase levels. Ann Intern Med (2002) 137:1-10.
Arora A., Goros G. The role of metals in ischemia/reperfusion injury of liver. Semin Liver Dis (1996) 16:31-38.
Boyd W.. The Intracellular distribution, latency and electrophortic mobility of L-glutamic oxaloacetic transaminase. Biochem J (1970) 8:433-438.
Inoue M., Protective mechanism against reactive oxygen species in : Arias M, Bojer L., Fansto N. et al. The liver biology and pathology. Raven Press, New York, USA. (1994) 443-459.
Downloads
Published
How to Cite
Issue
Section
License
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
